Detailed atomistic molecular modeling of a potent type ΙΙ p38α inhibitor
The active site conservation among protein kinases makes it a real challenge to design selective inhibitors. In this regard, detailed understanding of structural features responsible for functional behavior of different protein kinases is an important challenge in structure-based drug design. Amino acid decomposition analysis (ADA) is a powerful method to recognize and evaluate possible binding loci (hot spots) in ligand–receptor interaction. These hot spots could be used as a tool to differentiate selectivity profiles among similar protein kinases. p38α is a prominent target in the development of new anti-inflammatory agents. Type ΙΙ p38α inhibitors bind to DFG-out conformation of p38α in its inactive form. We performed a computational approach including MD simulations and ab initio method to evaluate a type ΙΙ p38α inhibitor. MD simulation was used to evaluate the binding pattern between ligand and p38α active site residues. Penetration of ligand thorough lipid bilayer was assessed by MD simulation using DPPC as a lipid bilayer model. Further conformational analysis was applied to determine induced ligand conformational instability due to binding to the receptor. ADA provided interesting results for pharmacophore discrimination. According to obtained results, residues Asp168, Leu167, Met109 and Glu71 had most contribution in binding to ligand. Conformational analysis showed that diffusion of ligand through lipid bilayer is done almost in nearly optimum structure. The obtained results could reveal some information on molecular basis of p38α inhibition, while being in good agreement with proposed pharmacophore in the literature.
Keywordsp38α MAPK Molecular dynamics Ab initio Conformational analysis
Financial supports of this project by research council of Hamadan University of Medical Sciences are acknowledged.
- 1.Hanks SK, Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9(8):576–596Google Scholar
- 2.Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Sci Signal 298(5600):1912–1934Google Scholar
- 4.Noble MEM, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Sci Signal 303(5665):1800–1805Google Scholar
- 25.de Brito MA, Rodrigues CR, Cirino JJV, Araújo JQ, Honório T, Cabral LM, de Alencastro RB, Castro HC, Albuquerque MG (2012) Residue–ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S-and NH-DABOs as non-nucleoside reverse transcriptase inhibitors. Molecules 17(7):7666–7694CrossRefGoogle Scholar
- 35.Bussi G, Donadio D, Parrinello M (2008) Canonical sampling through velocity-rescaling. arXiv preprint arXiv:08034060Google Scholar
- 42.Neese F (2011) ORCA—an ab initio, density functional and semiempirical program package, Version 2.8.0 University of BonnGoogle Scholar